{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:19:46Z","timestamp":1786961986329,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2017YFC1307600"],"award-info":[{"award-number":["2017YFC1307600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program of Liaoning Province","award":["2020JH1\/10300002"],"award-info":[{"award-number":["2020JH1\/10300002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04678-2","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:22:30Z","timestamp":1772580150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Songyue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"3","key":"4678_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352.","journal-title":"J Hepatol"},{"issue":"10290","key":"4678_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet (London, England). 2021;397(10290):2212\u201324.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"4678_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"1","key":"4678_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"9","key":"4678_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705.","journal-title":"Gut"},{"issue":"2","key":"4678_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3350\/cmh.2020.0239","volume":"27","author":"K Wijarnpreecha","year":"2021","unstructured":"Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(2):221\u201335.","journal-title":"Clin Mol Hepatol"},{"issue":"38","key":"4678_CR7","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"12","key":"4678_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"6","key":"4678_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919.","journal-title":"Hepatol Int"},{"key":"4678_CR10","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542."},{"issue":"11","key":"4678_CR11","first-page":"e114","volume":"152","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114\u2013218.","journal-title":"Circulation"},{"issue":"22","key":"4678_CR12","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"14","key":"4678_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268\u201379.","journal-title":"N Engl J Med"},{"issue":"10380","key":"4678_CR14","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(22)02603-4","volume":"401","author":"J He","year":"2023","unstructured":"He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401(10380):928\u201338.","journal-title":"Lancet"},{"issue":"10449","key":"4678_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet (London, England). 2024;404(10449):245\u201355.","journal-title":"Lancet (London, England)"},{"key":"4678_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111629","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111629.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4678_CR17","volume":"14","author":"G Hassen","year":"2022","unstructured":"Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-Leon GP, et al. Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease. Cureus. 2022;14(5):e25495.","journal-title":"Cureus"},{"key":"4678_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.934225","volume":"13","author":"W Wen","year":"2022","unstructured":"Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis. Front Endocrinol. 2022;13:934225.","journal-title":"Front Endocrinol"},{"key":"4678_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162511","author":"N Nasiri-Ansari","year":"2022","unstructured":"Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, et al. Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11162511.","journal-title":"Cells"},{"key":"4678_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/v15051072","author":"M Buchynskyi","year":"2023","unstructured":"Buchynskyi M, Kamyshna I, Oksenych V, Zavidniuk N, Kamyshnyi A. The intersection of COVID-19 and metabolic-associated fatty liver disease: an overview of the current evidence. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15051072.","journal-title":"Viruses"},{"issue":"2","key":"4678_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4678_CR22","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13\u2013115.","journal-title":"Hypertension"},{"issue":"33","key":"4678_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"key":"4678_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1539283","volume":"12","author":"Z Gao","year":"2025","unstructured":"Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med. 2025;12:1539283.","journal-title":"Front Med"},{"issue":"4","key":"4678_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41371-022-00686-w","volume":"37","author":"Q Huang","year":"2023","unstructured":"Huang Q, Yu H, Zhong X, Tian Y, Cui Z, Quan Z. Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study. J Hum Hypertens. 2023;37(4):313\u201320.","journal-title":"J Hum Hypertens"},{"issue":"10339","key":"4678_CR26","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0140-6736(22)00325-7","volume":"399","author":"Y Sun","year":"2022","unstructured":"Sun Y, Mu J, Wang DW, Ouyang N, Xing L, Guo X, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022;399(10339):1964\u201375.","journal-title":"Lancet"},{"issue":"25 Suppl 2","key":"4678_CR27","first-page":"S49","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.","journal-title":"Circulation"},{"issue":"10","key":"4678_CR28","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376\u2013414.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"4678_CR29","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","volume":"134","author":"HJ Zhang","year":"2021","unstructured":"Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. Chin Med J. 2021;134(13):1593\u2013601.","journal-title":"Chin Med J"},{"issue":"10","key":"4678_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clinical gastroenterology and hepatology\u202f: the official clinical practice journal of the American Gastroenterological Association. 2021;19(10):2138-2147.e2110.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"4","key":"4678_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u201391.","journal-title":"Hepatol Int"},{"issue":"1","key":"4678_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"4678_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4678_CR34","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022;107(2):e745\u201355.","journal-title":"J Clin Endocrinol Metab"},{"key":"4678_CR35","volume":"65","author":"JH Moon","year":"2023","unstructured":"Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinMed. 2023;65:102292.","journal-title":"EClinMed"},{"issue":"11","key":"4678_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022\u201332.","journal-title":"J Gastroenterol"},{"issue":"1","key":"4678_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03080-6","volume":"21","author":"Y Jia","year":"2023","unstructured":"Jia Y, Li D, You Y, Yu J, Jiang W, Liu Y, et al. Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank. BMC Med. 2023;21(1):398.","journal-title":"BMC Med"},{"issue":"2","key":"4678_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329\u201338.","journal-title":"J Clin Transl Hepatol"},{"key":"4678_CR39","volume":"384","author":"KS Kim","year":"2024","unstructured":"Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ (Clinical research ed). 2024;384:e076388.","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"4678_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, MD). 2016;64(1):73\u201384.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"4678_CR41","doi-asserted-by":"crossref","unstructured":"Dimitriadis K, Iliakis P, Vakka A, Pyrpyris N, Pitsillidi A, Tsioufis P, Fragkoulis C, Hering D, Weil J, Kollias A et al: Effects of sympathetic denervation in metabolism regulation: a novel approach for the treatment of MASLD? Cardiol Rev. 2025.","DOI":"10.1097\/CRD.0000000000000850"},{"key":"4678_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2022.104256","volume":"137","author":"Y Ling","year":"2023","unstructured":"Ling Y, Upadhyaya P, Chen L, Jiang X, Kim Y. Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: methodology review and benchmark. J Biomed Inform. 2023;137:104256.","journal-title":"J Biomed Inform"},{"issue":"11","key":"4678_CR43","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04678-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:29:21Z","timestamp":1775813361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04678-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4678"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04678-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CRHCP trial was approved by the ethics committees of the First Hospital of China Medical University (No. AF-SOP-07\u20131.2\u201301) and all participating institutes. All participants have signed written informed consent upon enrollment in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}